Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema
Status:
Not yet recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
It is a placebo-controlled randomized trial to evaluate the efficacy and safety of GNR-038 in
comparison with Berinert® in patients with hereditary angioedema
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
AO GENERIUM
Treatments:
Complement C1 Inactivator Proteins Complement C1 Inhibitor Protein Complement C1s